Healis review: the microdosing offer, total charge and cancellation cutoff

Healis advertises several care programs, including weight management and a separate GLP-1 microdosing offer. On the microdosing page, choosing the medicine changes both the price and the plan total. A $99 headline should therefore not be used as the price of every Healis weight-loss prescription.

The Low Dose checked Healis’ public pages and selected the medicine and billing-period controls on October 15, 2026. We did not proceed to checkout, submit a medical questionnaire or test treatment. The figures below are observed promotional displays, not a personalized invoice, future-price guarantee or numerical quality rating.

The selected plan tells you more than the headline

The microdosing offer displays a first-plan promotion. Its semaglutide selector showed $129 billed today for the monthly option and $297 billed today for three months, expressed as $99 per month. The tirzepatide selector showed $179 billed today monthly or $357 billed today for three months, expressed as $119 per month.

The page also displays crossed-out comparison prices and savings amounts. Those comparison figures do not by themselves establish the exact next renewal price. Because the banner calls this a first-plan offer, save the checkout terms showing the first total, next total and any change after the promotional period. A three-month monthly equivalent is not three monthly installments.

The broader homepage advertises weight-management care from $149, alongside other services. That is a different program description from the selected microdosing offer. Do not combine one program’s starting price, another’s benefits and a third product’s billing interval into an assumed bundle.

What is included, and when does payment occur?

The expanded offer FAQ says an approved plan includes medication, clinician review, weekly check-ins and free shipping. Its ordering instructions put checkout before the medical questionnaire and promise an automatic full refund if the clinician does not approve treatment. This is the advertised process; no refund or clinical review was tested.

The cancellation and refund policy, dated June 15, 2026, instead describes the subscription beginning when intake is completed and the first month is charged. It also says the exact mix of consultations, lab services, support and medication can vary by subscription. Clarify the selected offer’s charge timing and whether any outside testing or additional service is separate.

Two different seventy-two-hour rules

The cancellation policy requires a request at least seventy-two hours before the billing date. If the notice arrives late, the next charge occurs and cancellation takes effect on the following billing date. Requests go through customer service or the account process where available; obtain written confirmation of the effective date.

A separate refund provision applies within the first seventy-two hours of the subscription term if no subscription services have been received. That is not the same as the seventy-two-hour advance cancellation deadline, and it is not a blanket trial period after using the service. Monthly plans generally receive no refund for the cancellation month or earlier months.

The offer’s expanded refund FAQ also says unopened product can be returned within fourteen days of delivery for a full refund. That conflicts with the general policy’s restriction on prescription returns and its subscription refund conditions. We did not establish which products qualify for that advertised return window. Obtain a written explanation for the exact prescribed product before treating it as a return guarantee.

For subscriptions charged for two or more months at once, the policy says refunds cover months for which no medication was shipped. It limits approved refunds to the most recent billing cycle and discusses replacement of damaged or incorrect medication. It does not support assuming that every unused dose or partly used vial will be refunded.

The policy promises a full refund for medical disqualification at enrollment, while its later provisions discuss remaining subscription charges and possible refunds after eligibility changes. Ask which fees are included in the relevant exception. Its final paragraph says patients remain responsible for services already rendered and that this policy governs subscription fees.

The terms identify the platform and clinical partner

The March 30, 2026 terms identify Healis LLC and a partnership with OpenLoop Health Inc. for certain clinical, telehealth and fulfillment functions. They distinguish independent providers from the platform and allow prescriptions to be sent or transferred to partner pharmacies, subject to the program and location.

The reviewed terms do not identify the actual prescriber or pharmacy for a specific microdosing order. Obtain those names, the exact formulation and dispensing instructions. The terms also say recurring charges continue until canceled and refer to the cutoff disclosed at checkout or in the account. Their example of a forty-eight-hour cutoff is not a universal rule; reconcile it with the policy’s explicit seventy-two-hour requirement before enrolling.

Microdosing claims still need clinical evidence

The offer markets a lower starting dose and fewer side effects, and labels tirzepatide as the faster-results option. Those are commercial claims, not outcomes independently established for this particular program by the pages reviewed. A lower advertised dose does not by itself prove greater safety or suitability for women over forty.

Where a prescription is compounded, it is not an FDA-approved product. The FDA explains the approval and safety-evidence limits of compounded GLP-1 drugs. This review provides no microdosing regimen, conversion instruction or evidence that a promotional program reproduces branded-drug trial results.

Keep the treatment decision separate from the billing choice. Confirm the clinician’s recommendation, first and next totals, exact supply period and cancellation confirmation. The Contour Health review shows why a by-the-vial program should not be compared with a renewing three-month plan using monthly equivalents alone.